To this group belong, for example, upadacitinib, the first selective JAK inhibitor approved for RA, and filgotinib, both able to act selectively against JAK1, and decernotinib and ritlecitinib, selective for JAK3. This evidence concerns the gene JAK1 and rheumatoid arthritis.